A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new ...

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers, and it has potential with other cancers as well.

New data showed that prior malignancy may influence survival outcomes in patients with metastatic colorectal cancer, ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal ...

Ultimately, if we can predict cancer’s next move, we can beat it.” Image: Patient-derived High-Grade Serous Ovarian Carcinoma (HGSOC) organoids grown, fixed and imaged in ICR laboratories. Cells were ...

When tumor cells leave ascites, it can be observed that their proliferation ability is significantly weakened. In ovarian cancer, ascites occurs in a considerable proportion of patients, and the ...

Most women with epithelial ovarian cancer are diagnosed with stage III ... repeated paracentesis for ascites, and/or multiple thoracentesis for pleural effusions 1A Growth limited to one ovary ...

Ovarian cancer is the sixth most common cancer worldwide ... repeated paracentesis for ascites, and/or multiple thoracentesis for pleural effusions 1A Growth limited to one ovary; no tumor on ...